Liquidia Corporation (LQDA)
NASDAQ: LQDA
· Real-Time Price · USD
14.13
0.03 (0.21%)
At close: Jun 16, 2025, 3:59 PM
14.04
-0.67%
After-hours: Jun 16, 2025, 07:58 PM EDT
0.21% (1D)
| Bid | 14 |
| Market Cap | 1.21B |
| Revenue (ttm) | 14.14M |
| Net Income (ttm) | -127.83M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -8.27 |
| Forward PE | -70.47 |
| Analyst | Buy |
| Ask | 15.14 |
| Volume | 1,198,057 |
| Avg. Volume (20D) | 1,825,349 |
| Open | 14.25 |
| Previous Close | 14.10 |
| Day's Range | 14.01 - 14.62 |
| 52-Week Range | 8.26 - 19.41 |
| Beta | 0.04 |
About LQDA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LQDA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LQDA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-16.87%
Liquidia shares are trading lower in reaction to I...
Unlock content with
Pro Subscription
2 weeks ago
+13.07%
Liquidia shares are trading higher after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.
1 week ago · https://thefly.com
Liquidia price target lowered by $2 at BofA, here's whyLiquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
